Price
162.33
-0.13%52W Range
Market Cap
₹567.53 Cr
Traded: ₹0.65 Cr (0.11%) 0.0x
Free Float: ₹159.70 Cr (0.41% of FF traded)
Volume · 60D trend
40 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +27.0% | +28.0% | +19.0% | -- | +14.0% | Decelerating |
| Profit | +16.0% | +55.0% | +38.0% | -- | +7.0% | Decelerating |
| Return | +28.0% | +15.0% | +27.0% | -10.0% | -- | Stable |
| ROE | +5.0% | +9.0% | +10.0% | -- | -- | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 45 | 90 | 54 | 49 | 43 | 61 | 56 | 47 | 33 | 45 | 32 | 41 | 37 | 45 | 30 | 31 |
| Expenses | 42 | 67 | 48 | 44 | 40 | 47 | 47 | 41 | 32 | 38 | 30 | 33 | 30 | 39 | 26 | 27 |
| Operating Profit | 3 | 22 | 6 | 5 | 3 | 15 | 9 | 6 | 2 | 7 | 2 | 9 | 6 | 6 | 4 | 4 |
| OPM % | 6.5% | 24.7% | 11.4% | 10.3% | 7.6% | 23.8% | 15.5% | 12.8% | 5.0% | 15.8% | 7.2% | 20.9% | 16.9% | 14.0% | 13.3% | 12.9% |
| Other Income | 3 | 0 | 2 | 7 | 3 | 2 | 2 | 5 | 3 | 0 | 3 | 0 | 1 | 1 | 1 | 0 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 4 | 20 | 6 | 9 | 3 | 14 | 8 | 10 | 2 | 5 | 3 | 7 | 5 | 5 | 2 | 2 |
| Tax % | 48.8% | 26.4% | 22.9% | 14.5% | 34.5% | 26.2% | 32.0% | 16.7% | 93.3% | 30.6% | 38.2% | 24.9% | 32.7% | 43.0% | 30.6% | -25.2% |
| Net Profit | 2 | 15 | 4 | 8 | 2 | 10 | 6 | 9 | 0 | 4 | 2 | 5 | 3 | 3 | 2 | 2 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.8 | 4.2 | 1.3 | 2.3 | 0.9 | 3.0 | 1.7 | 2.5 | 0.4 | 1.0 | 0.8 | 1.4 | 1.0 | 1.1 | 1.4 | 1.4 |
| Sales Growth (YoY) | 4.0% | 46.3% | -4.2% | 3.0% | 29.0% | 36.6% | 76.7% | 15.2% | -8.5% | -0.4% | 6.1% | 34.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -49.9% | 66.5% | 10.0% | 13.4% | -29.5% | 9.0% | 18.3% | 41.9% | -25.4% | 41.0% | -22.8% | 12.7% | -18.8% | 50.1% | -2.4% | -- |
| OP Growth (YoY) | -9.8% | 51.7% | -29.6% | -17.4% | 96.4% | 106.1% | 282.9% | -29.2% | -73.1% | 18.0% | -42.7% | 118.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | -86.7% | 260.0% | 22.0% | 54.6% | -77.7% | 67.1% | 43.1% | 267.5% | -76.6% | 210.5% | -73.5% | 39.5% | 3.0% | 50.8% | 0.8% | -- |
| Profit Growth (YoY) | -4.0% | 39.6% | -25.7% | -5.0% | 126.1% | 189.7% | 104.8% | 81.9% | -60.1% | 0.8% | 22.8% | 95.1% | 60.8% | 22.8% | 111.6% | 12.5% |
| EPS Growth (YoY) | -4.6% | 39.7% | -25.3% | -4.9% | 128.9% | 188.3% | 104.8% | 82.2% | -61.6% | -1.9% | -40.7% | -6.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -80.0% | 226.8% | -45.7% | 169.0% | -70.7% | 74.7% | -30.9% | 547.4% | -63.1% | 24.1% | -38.5% | 36.4% | -5.7% | -25.0% | -2.8% | -- |
| OP Margin | 6.5% | 24.7% | 11.4% | 10.3% | 7.6% | 23.8% | 15.5% | 12.8% | 5.0% | 15.8% | 7.2% | 20.9% | 16.9% | 13.3% | 13.3% | 12.9% |
| Net Margin | 4.4% | 16.6% | 8.0% | 16.4% | 5.3% | 16.7% | 10.0% | 18.1% | 0.3% | 8.2% | 5.5% | 12.3% | 8.4% | 6.7% | 5.7% | 6.3% |
| Material Cost % | 53.0% | 49.0% | 57.0% | 54.0% | 57.0% | 47.0% | 58.0% | 52.0% | 55.0% | 55.0% | 53.0% | 49.0% | 47.0% | 56.2% | 46.0% | 50.0% |
| Employee Cost % | 9.0% | 5.0% | 7.0% | 8.0% | 6.0% | 5.0% | 6.0% | 5.0% | 8.0% | 5.0% | 8.0% | 6.0% | 7.0% | 6.3% | 10.0% | 10.0% |
| P/S | 2.39 | 2.83 | 2.59 | 2.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 18.90 | 22.16 | 10.32 | 20.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.03 | 2.39 | 2.03 | 2.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50We are submitting herewith the monitoring agency report
We are submitting herewith the publication of extract of the financial results for the quarter ended 30th June 2026
Submission of financial results for the quarter ended 30th June 2026
We are submitting herewith the financial results for the quarter ended 30th June 2026
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve unaudited standalone and ....
We are hereby submitting the notice of Annual General Meeting schedule to be held on Thursday, 27th August, 2026
We are submitting herewith the annual report for the FY 2025-26
Outcome of board meeting is enclosed for ready reference
We are submitting herewith the certification under regulation 74(5) of SEBI (DP) Regulations
We are submitting herewith the intimation of Closure of window
We are pleased to inform you that we have commenced the Nutraceutical Manufacturing Block of our new plant located at 24/2/1/1 Maldev, Pen, Raigad, Maharashtra India today. i.e 17th June, 2026
We are hereby submitting annual secretarial compliance report for the year ended 31st March, 2026
We are submitting hereby copy of newspaper publication of the extract of financial results for the quarter ended 31st March, 2026
We are hereby submitting the monitoring agency report for the quarter ended 31st March, 2026
We are hereby submitting audited standalone and consolidated financial results of the Company for the quarter ended 31st March, 2026
We are hereby submitting audited standalone and consolidated financial results for the quarter ended 31st March, 2026
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve the audited financial results ....
We are hereby submitting certificate under regulation 74(5) of SEBI (DP) Regulations received from MUFG Intime India Private Limited, RTA of the Company
Closure of Trading Window
Board approved the allotment of bonus equity shares in the ratio of 1:1
We hereby inform you that the Company has fixed Tuesday, 24th March, 2026 as record date in order to determine the number of shareholders entitled for bonus equity shares in the ratio of 1:1
We are submitting herewith the Scrutinizer''s Report
We hereby submit proceeding of EGM
We are submitting herewith the copy of paper publication of EGM Notice
We are submitting herewith the notice of EGM to be held on 13th March, 2026
We are submitting herewith the copy of monitoring agency report for the quarter ended 31st December, 2025
Submitting herewith the newspaper publication of extract of financial results for the quarter ended 31st December, 2025
Outcome of Board meeting is enclosed
Please find attached unaudited standalone and consolidated financial results for the year ended 31st December 2026
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve unaudited quarterly financial ....
We are submitting herewith the certificate under regulation74(5) received from our RTA
Trading window will be closed with effect from 1st January 2026 till expiry of 48 hours from the declaration of unaudited financial results of the company for the quarter ended 31st December, 2025
We are hereby submitting the copy publication of extract of financial results for the quarter ended 30th September, 2025
We are submitting herewith the report received from monitoring agency for the quarter ended 30th September, 2025
We are submitting herewith the Press Release of Financial Results for H126
We are hereby submitting the Outcome Of Board Meeting
We are hereby submitting the unaudited financial results for the quarter ended 30th September, 2025
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve Consideration and Approval ....
We are submitting herewith the certificate received from MUFG Intime India Private Limited for the quarter ended 30th September, 2025 under Regulation 74(5) of SEBI (DP) Regulations
We are submitting the scrutinizer report
The trading window will be closed for all designated person of the Company with effect from 1st October, 2025 and will remain close till 48 hours from the declaration of financial results
We are enclosing herewith the proceeding and outcome of 33rd Annual General Meeting of the Company.
We are submitting herewith the letter dispatched to shareholders regarding the availability of annual report for fy 2024-25 in the website of the Company
Submission of Newspaper Publication of 33rd AGM notice of the Company
Book Closure Intimation
We are hereby submitting herewith the notice of annual general meeting for your record
We are hereby submitting the Annual Report for the FY 2024-25
Submission of Newspaper Publication
Postponement of credit of right issue and listing of shares
Outcome of board meeting for allotment of right issue shares
Annual Reports
16Concalls
2Jun 2024
30 Jun 2024Jun 2023
30 Jun 2023